Viewing nowCivas Tablet (Simvastatin)
Simvastatin 20mg
Tablet · Prescription medication
Huons Co., Ltd.

MFDS item code 200403126 · Notified 2004.01.28 · Insurance code 670601380
Improvement of hyperlipidemia, improvement of pediatric familial hypercholesterolemia, and prevention of cardiovascular disease
This medication helps lower the risk of cardiovascular disease. It reduces the risk of cardiovascular disease and cerebrovascular accidents in adult patients with a history of coronary heart disease, diabetes, peripheral vascular disease, or stroke. Additionally, it is effective in lowering total cholesterol, bad LDL cholesterol, Apo-B protein, and triglyceride levels in patients with hyperlipidemia, while raising good HDL cholesterol levels. This medication is particularly helpful for patients with familial hypercholesterolemia or in pediatric patients who have high lipid levels despite dietary interventions. This drug is used to reduce the risk of cardiovascular disease and to improve dyslipidemia.
Patients must follow a standard cholesterol-lowering diet before and during treatment with this drug. 1. Reduction of risk of cardiovascular disease Adult patients at high risk of coronary heart disease events due to a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended initial dose is 20 mg of this drug once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this drug. Administration of 5 ~ 40 mg of this drug once daily in the evening is recommended. Adjust the dose appropriately according to the initial LDL cholesterol level before starting treatment, the treatment goal, and the patient's response to the drug. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if the cholesterol level falls below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, the 80 mg dose of this drug, particularly during the first year of treatment, should be used only in patients who have taken 80 mg of this drug for 12 months or longer without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) Refer below for recommended doses in patients receiving this drug concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in certain patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment) (see 6. Drug Interactions under Precautions for Use). (1) Use in patients with homozygous familial hypercholesterolemia Based on the results of controlled clinical trials, patients with homozygous familial hypercholesterolemia should receive 40 mg of this drug once daily in the evening. This drug should be used in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when other lipid-lowering treatments are not available. (2) In elderly patients, the maximum reduction in cholesterol levels may be achieved with a daily dose of 20 mg of this drug. (3) Use in patients receiving verapamil, diltiazem, or dronedarone When this drug is administered concomitantly to patients receiving verapamil, diltiazem, or dronedarone, the dose of this drug must not exceed 10 mg per day. (4) Use in patients receiving amiodarone, amlodipine, or ranolazine When this drug is administered concomitantly to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this drug must not exceed 20 mg per day. (5) Concomitant use with other lipid-lowering agents This drug is effective when administered alone or in combination with a bile acid sequestrant. When this drug is administered concomitantly with a fibrate (excluding gemfibrozil (see 2. Patients in Whom the Drug Must Not Be Administered under Precautions for Use) and fenofibrate), the dose of this drug must not exceed 10 mg per day. (6) Use in patients with renal impairment Because this drug is not extensively excreted by the kidneys, no dose adjustment is necessary in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, start treatment at 5 mg per day and monitor carefully.
Pediatric patients aged 10 ~ 17 years with heterozygous familial hypercholesterolemia: The recommended initial dose is 10 mg of this drug once daily in the evening. The recommended dose range is 10 ~ 40 mg per day, and the recommended maximum dose is 40 mg per day. Adjust the dose appropriately for each patient according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.
This medication carries a risk of muscle-related side effects such as myopathy and rhabdomyolysis. The risk may be higher with high doses or when taken with certain medications. This medication should not be used in individuals who are allergic to this drug or its components, those with severely impaired liver function, pregnant or breastfeeding women, and those currently taking strong CYP3A4 inhibitors. Care should be taken with patients who have impaired liver or kidney function, hypothyroidism, or a history of muscle disease, as well as in elderly patients and women. During treatment, patients should inform their physician immediately if they experience symptoms such as muscle pain, weakness, or tenderness, and should discontinue use if these symptoms occur. This medication can affect liver function, so it is important to undergo regular liver function tests before and during treatment. Interactions with other medications may occur during treatment, so it is essential to inform healthcare providers of this medication when prescribed new medications. Women who are pregnant or may become pregnant must use contraception, and treatment should be stopped immediately if pregnancy is confirmed. During breastfeeding, this medication can be passed into breast milk; thus, it is safe to discontinue breastfeeding while taking this medication. Children under 10 years of age and females before menarche have not been established as safe to use. Elderly patients have a higher risk of muscle side effects, necessitating increased caution during treatment. Severe side effects can occur with overdose, so strictly adhere to the prescribed dosage. When storing this medication, keep it out of reach of children, in its original container, and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to keep out air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve the drug's effectiveness over time.
For domestic use: Brownish-yellow oval film-coated tablet For export: Brownish-yellow round film-coated tablet
30 tablets/bottle, 300 tablets/bottle, 100 tablets/bottle (for export)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSimvastatin 20mg
Tablet · Prescription medication
Huons Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
Jongkundang Pharmaceutical Co., Ltd.
Simvastatin 20mg
Tablet · Prescription medication
Dong-A ST Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
Korea Hutech Pharmaceutical Co., Ltd.
Simvastatin 20mg
Tablet · Prescription medication
Yuhan Corporation

Simvastatin 40mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
Dongsung Pharmaceutical Co., Ltd.

Simvastatin 20mg
Tablet · Prescription medication
HK inno.N Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.